Multiple sclerosis (MS) is an inflammatory and demyelinating disorder of the central nervous system affecting 2.3 million people worldwide. Myelin is a sheath around nerves that aids in conducting nerve impulses. Demyelination is a breakdown of this sheath. It is not reversible naturally or through existing drugs. As MS progresses, it affects muscles, nerves, and joints, causing significant pain, as well as spasms, stiffness, tremors, body mobility limitations and weakness, difficulty chewing, swallowing, and speaking.
Currently, there are several approved drugs on the market for MS, all of which are primarily for the relief of symptoms and none are disease-modifying or curative.
Systemic Sclerosis, A form of Scleroderma
Systemic sclerosis (SSc), is a chronic, rare systemic autoimmune disease that causes fibrosis, or thickening and scarring, of skin and internal organs. It affects approximately 200,000 people in the U.S., EU and Japan.
Currently, there is no cure for systemic sclerosis and approved therapies on the market today only address symptoms and are associated with toxicity.
EHP has received Orphan Drug Designation for EHP-101 in SSc from both the US FDA and EMA.
Parkinson’s Disease (PD)
Parkinson’s disease is an incurable neurodegenerative disorder affecting nearly 10 million people worldwide. Primarily, it is a disease where the nerve cells stop producing a substance called dopamine, which helps transmit impulses from the brain to the muscles. The disease results in tremors, slowness and stiffness, impaired balance, and rigidity of the muscles. These symptoms get worse over time.
Currently, there is no cure for Parkinson’s disease but there are available treatments that manage problems with walking, movement and tremor.
Huntington’s Disease (HD)
Huntington’s disease is an inherited disease that causes the progressive breakdown of nerve cells in the brain It causes uncontrolled movements, emotional problems, loss of thinking (cognition) and deteriorates patients’ physical and mental abilities to the extent that they are unable to care for themselves. It has no cure. In the US, approximately 30,000 people are symptomatic and more than 200,000 are at risk of inheriting the disease. In Europe, 3 to 7 per 100,000 people are affected.
Currently, there are no drugs to slow or stop the progression of Huntington’s disease. There are specific drugs available to reduce some of the symptoms.
EHP has received Orphan Drug Designation for EHP-102 in HD from the US FDA and has applied to the EMA for Orphan Drug Designation.